Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carboplatin + Raludotatug deruxtecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Raludotatug deruxtecan | DS 6000a|DS-6000|DS6000a|DS-6000a|R-DXd|MK-5909 | Raludotatug deruxtecan (DS-6000a) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH6 linked to the cytotoxic DNA topoisomerase inhibitor DXd, which binds to CDH6 expressed on tumor cells and potentially induces tumor cell apoptosis and inhibits tumor growth (PMID: 38205802). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06843447 | Phase Ib/II | Pembrolizumab + Raludotatug deruxtecan Carboplatin + Raludotatug deruxtecan Paclitaxel + Raludotatug deruxtecan Bevacizumab + Raludotatug deruxtecan | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | Recruiting | USA | ISR | GBR | ESP | 0 |